company background image
MCK logo

McKesson NYSE:MCK Stock Report

Last Price

US$533.64

Market Cap

US$70.1b

7D

1.3%

1Y

54.6%

Updated

18 Mar, 2024

Data

Company Financials +

MCK Stock Overview

McKesson Corporation provides healthcare services in the United States and internationally.

MCK fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance2/6
Financial Health2/6
Dividends0/6

McKesson Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for McKesson
Historical stock prices
Current Share PriceUS$533.64
52 Week HighUS$537.26
52 Week LowUS$334.79
Beta0.44
1 Month Change4.42%
3 Month Change19.11%
1 Year Change54.57%
3 Year Change177.39%
5 Year Change361.43%
Change since IPO3,134.18%

Recent News & Updates

Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

Mar 14
Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

McKesson: GLP-1 Contributed More Than 1/3 Of Growth

Feb 19

McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Feb 16
McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Recent updates

Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

Mar 14
Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

McKesson: GLP-1 Contributed More Than 1/3 Of Growth

Feb 19

McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Feb 16
McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

Jan 29
Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

McKesson: Why The Company Is Too Richly Valued

Jan 19

If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

Nov 20
If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase

Nov 08

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

Oct 30
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

McKesson: Still Trading For A Huge Discount

Sep 06

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Aug 21
Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

Jul 27
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation

Jun 28

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

May 23
Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?

Apr 17
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?

Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?

Feb 22
Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?

McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth

Feb 08

McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M

Feb 01

McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

Jan 12
McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

5 Reasons Why I Am Considering Adding McKesson To My Portfolio

Dec 27

McKesson Corporation: Still Trading Below Intrinsic Value

Dec 13

Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus

Oct 08

McKesson extends distribution partnership with CVS Health

Sep 29

An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued

Sep 19
An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued

McKesson to acquire Rx Savings Solutions in $875M deal

Sep 19

Cardinal Health, McKesson hit 52-week highs; up 35% and 50% YTD

Aug 15

McKesson raises fiscal 2023 adjusted diluted EPS following strong quarterly results

Aug 03

McKesson raises dividend by 15% to $0.54/share

Jul 25

McKesson Is Still An Attractive Dividend Growth Stock

Jul 10

McKesson: Best Of Breed In Drug Distributor Oligopoly

Jun 20

McKesson: Still Profitable Without COVID-19 Boosts

Jun 04

Shareholder Returns

MCKUS HealthcareUS Market
7D1.3%0.3%-0.1%
1Y54.6%6.1%28.4%

Return vs Industry: MCK exceeded the US Healthcare industry which returned 6.1% over the past year.

Return vs Market: MCK exceeded the US Market which returned 28.4% over the past year.

Price Volatility

Is MCK's price volatile compared to industry and market?
MCK volatility
MCK Average Weekly Movement2.5%
Healthcare Industry Average Movement7.3%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: MCK has not had significant price volatility in the past 3 months.

Volatility Over Time: MCK's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
183348,000Brian Tylerhttps://www.mckesson.com

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.

McKesson Corporation Fundamentals Summary

How do McKesson's earnings and revenue compare to its market cap?
MCK fundamental statistics
Market capUS$70.12b
Earnings (TTM)US$3.00b
Revenue (TTM)US$301.51b

23.4x

P/E Ratio

0.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MCK income statement (TTM)
RevenueUS$301.51b
Cost of RevenueUS$289.33b
Gross ProfitUS$12.18b
Other ExpensesUS$9.18b
EarningsUS$3.00b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)22.81
Gross Margin4.04%
Net Profit Margin0.99%
Debt/Equity Ratio-338.3%

How did MCK perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

10%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.